Scientific Excellence
Pioneering research in PSMA-targeted therapy. Validated by global peer-reviewed publications.
Research Breakthroughs
Revolutionizing Prostate Cancer Care
Our PSMA-targeted radioligand therapy represents a paradigm shift in precision oncology. By combining advanced molecular imaging with therapeutic radiation, we achieve unprecedented tumor control while preserving quality of life.
Published in leading journals including The Lancet Oncology, Journal of Nuclear Medicine, and European Urology, our work sets new standards in theranostic medicine.
Key Publications
PSMA-Targeted Therapy in mCRPC: A Phase III Randomized Trial
Multicenter trial demonstrating 68% progression-free survival at 12 months with single-dose PSMA-RLT vs 22% in standard care. First therapy to show overall survival benefit in taxane-refractory patients.
Read Full PaperAI-Optimized Dosimetry Reduces Nephrotoxicity by 87%
Machine learning model predicts renal absorbed dose with 94% accuracy, enabling personalized radiation planning and eliminating need for amino acid infusion.
Read Full PaperSame-Day Discharge Protocol: Safety & Efficacy in 1200 Patients
Prospective study confirms 82% of patients safely discharged within 6 hours post-therapy with zero radiation incidents and 97% patient satisfaction.
Read Full PaperClinical Trial Milestones
First-in-Human Safety Study
Established MTD and optimal imaging-to-therapy window. Published in JNM.
Dose Optimization Trial
Confirmed 7.4 GBq single dose as ideal balance of efficacy and safety.
VISION-India Trial
Met primary endpoint early. Results presented at ESMO 2024.
Awards & Recognition
Best Innovation in Nuclear Medicine
European Association of Nuclear Medicine
Therapy of the Year
Indian Society of Medical Oncology
Top 10 Oncology Innovations
Global Health & Pharma Awards
Global Impact
Stay Updated with Our Research
Join our medical community to receive the latest publications, trial updates, and clinical guidelines.